Celltrion Reports Results of Remsima SC (biosimilar, infliximab) in a Clinical Study for Active Crohn’s Disease and Ulcerative Colitis #ECCO2020

 Celltrion Reports Results of Remsima SC (biosimilar, infliximab) in a Clinical Study for Active Crohn’s Disease and Ulcerative Colitis #ECCO2020

Celltrion Reports Results of Remsima SC (biosimilar, infliximab) in a Clinical Study for Active Crohn’s Disease and Ulcerative Colitis #ECCO2020

Shots:

  • The clinical study involves assessing the PK, efficacy, and safety of CT-P13 SC vs CT-P13 IV in 131 patients with active CD & UC for 1yr. Following loading doses of IV 5mg/kg @0 & 2wks., patients were randomized @6wks. to receive either SC 120/240 mg q2w or continued IV 5 mg/kg q8w, @30wks. IV arm switched to SC arm based on body weight
  • The clinical study results demonstrated that Remsima SC is comparable to its IV formulation @1yr., improvement in clinical activity, rate of clinical response and remission are maintained, improvement in the rate of clinical healing
  •  Remsima SC (CT-P13 SC) is the first & only SC infliximab to be available in EU with its expected approval in EU for IBD in mid-2020 and has received EMA’s MAA for RA in H2’19

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: PRO EXPO

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post